检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

Shaji K Kumar,Natalie S Callander,Kehinde Adekola,Larry D Anderson,Muhamed Baljevic,Rachid Baz,Erica Campagnaro,Jorge J Castillo,Caitlin Costello, Christopher D'Angelo,Benjamin Derman,Srinivas Devarakonda,Noura Elsedawy,Alfred Garfall,Kelly Godby,Jens Hillengass,Leona Holmberg,Myo Htut, Carol Ann Huff,Malin Hultcrantz,Yubin Kang,Sarah Larson,Hans Lee,Michaela Liedtke,Thomas Martin,James Omel, Timothy Robinson,Aaron Rosenberg,Douglas Sborov,Mark A Schroeder,Daniel Sherbenou,Attaya Suvannasankha,Jason Valent,Asya Nina Varshavsky-Yanovsky, Jenna Snedeker,Rashmi Kumar

Journal of the National Comprehensive Cancer Network : JNCCN（2024）

引用 0|浏览13
暂无评分
摘要
The treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a framework on which to base decisions regarding diagnosis, treatment, assessment of response to treatment, and follow-up of both newly diagnosed and previously treated WM/LPL.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要